Paratek Pharmaceuticals Acknowledges Receipt Of NexPoint Letter; Says Co's Board Of Directors Respectfully Disagrees With NexPoint's Characterizations Contained In Its Letter
Portfolio Pulse from Happy Mohamed
Paratek Pharmaceuticals (NASDAQ:PRTK) has acknowledged receipt of a letter from NexPoint Asset Management, but disagrees with its characterizations. Paratek will provide additional details on its acquisition by Gurnet Point Capital and Novo Holdings A/S when it files proxy materials with the SEC.

June 27, 2023 | 4:04 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Paratek Pharmaceuticals disagrees with NexPoint's characterizations in its letter. The company will provide more information on its acquisition by Gurnet Point Capital and Novo Holdings A/S.
Paratek Pharmaceuticals has acknowledged the receipt of a letter from NexPoint Asset Management but disagrees with its characterizations. The company will provide more information on its acquisition by Gurnet Point Capital and Novo Holdings A/S when it files proxy materials with the SEC. This news may not have a significant short-term impact on the stock price, but it shows that Paratek is addressing concerns from its stockholders.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100